Related Experiment Video
Updated: Jun 9, 2026
Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
BRAF testing in advanced colorectal cancer: is it ready for prime time?
Brooke Phillips1, Matthew Kalady, Richard Kim
1Department of Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Abstract:
Given that KRAS mutant colorectal tumors do not respond to anti-EGFR monoclonal antibodies such as cetuximab or panitumumab, it is now standard that all patients with metastatic colorectal cancer who are candidates for these therapies undergo KRAS testing. BRAF encodes a protein kinase, which is involved in intracellular signaling and cell growth and is a principal downstream effector of KRAS. BRAF is now increasingly being investigated in metastatic colorectal carcinoma. BRAF mutations occur in less than 10-15% of tumors and appear to be poor prognostic markers. However the predictive nature of this biomarker is yet undefined. This article will review the evidence behind both KRAS and BRAF testing in metastatic colorectal cancer.
Insights
KRAS mutations predict resistance to anti-EGFR therapies in metastatic colorectal cancer. BRAF mutations are common, but their predictive role in colorectal cancer requires further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- KRAS mutations are established predictors of resistance to anti-EGFR monoclonal antibodies (e.g., cetuximab, panitumumab) in metastatic colorectal cancer (mCRC).
- BRAF, a downstream effector of KRAS, is increasingly studied in mCRC, with mutations found in 10-15% of tumors.
- BRAF mutations are associated with poor prognosis in mCRC, but their predictive value for targeted therapies remains unclear.
Purpose of the Study:
- To review the current evidence for KRAS testing in metastatic colorectal cancer.
- To discuss the emerging role and predictive potential of BRAF mutations in metastatic colorectal cancer.
Main Methods:
- Literature review of studies investigating KRAS and BRAF mutations in metastatic colorectal cancer.
- Analysis of the predictive and prognostic significance of these biomarkers in relation to treatment response.
Main Results:
- KRAS testing is standard for patients with mCRC considered for anti-EGFR therapy due to non-response in KRAS-mutant tumors.
- BRAF mutations are identified as potential poor prognostic markers in mCRC.
- The predictive utility of BRAF mutations for specific therapies is still under investigation.
Conclusions:
- KRAS testing is essential for guiding anti-EGFR therapy selection in metastatic colorectal cancer.
- Further research is needed to define the predictive value of BRAF mutations in metastatic colorectal cancer treatment strategies.
